Meeting report: Vienna 2008 Workshop of the German - Austrian Working Group for Studying Prognostic Factors in Myelodysplastic Syndromes

Annals of Hematology

Volumn 88, Issue 7, 2009, Pages 607-611

  Valent, Peter ^a   Hofmann, Wolf Karsten ^b   Büsche, Guntram ^c   Sotlar, Karl ^d   Horny, Hans Peter ^e   Haase, Detlef ^f   Haferlach, Torsten ^g   Kern, Wolfgang ^g   Bettelheim, Peter ^h   Baumgartner, Christian ^a   Sperr, Wolfgang R ^a   Nösslinger, Thomas ⁱ   Wimazal, Friedrich ^a   Giagounidis, Aristoteles A ^j   Lübbert, Michael ^k   Krieger, Otto ^l   Kolb, Hans Jochem ^d   Stauder, Reinhard ^m   Pfeilstöcker, Michael ⁱ   Gattermann, Norbert ⁿ   Fonatsch, Christa ^a   Aul, Carlo ^j   Germing, Ulrich ⁿ   more..

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e Klinikum Ansbach   (Germany)

^f UNIVERSITY OF GÖTTINGEN   (Germany)

^g MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^h OTTO WAGNER HOSPITAL   (Austria)

ⁱ HANUSCH HOSPITAL   (Austria)

^j ST JOHANNES HOSPITAL   (Germany)

^k UNIVERSITY OF FREIBURG   (Germany)

^l ELISABETHINEN HOSPITAL   (Austria)

^m INNSBRUCK MEDICAL UNIVERSITY   (Austria)

ⁿ HEINRICH HEINE UNIVERSITY   (Germany)

more..

Author keywords

Criteria; MDS registry; Myelodysplastic syndromes; Prognostication; Standardization

Indexed keywords

MOLECULAR MARKER;

AUSTRIA; AWARENESS; CONFERENCE PAPER; CYTOGENETICS; DISEASE CLASSIFICATION; FLOW CYTOMETRY; GENETIC VARIABILITY; GERMANY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; SWITZERLAND; WORKSHOP;

AUSTRIA; BIOLOGICAL MARKERS; CYTOGENETIC ANALYSIS; DIAGNOSTIC TECHNIQUES AND PROCEDURES; FLOW CYTOMETRY; GERMANY; HUMANS; IMMUNOHISTOCHEMISTRY; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; SWITZERLAND;

EID: 67349168719     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-008-0673-7     Document Type: Conference Paper

References (34)

1. Valent P, Horny HP, Bennett JM et al (2007) Definitions and standards in the diagnosis and treatment of the myelodysplastic sydromes: Consensus statements and report from a working conference. Leuk Res 31:727-736 doi: 10.1016/j.leukres.2006.11.009
2. Bennett JM (2000) World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol 72:131-133
3. Brunning R, Orazi A, Germing U et al (2008) Myelodysplastic syndromes/ neoplasms, overview. In: Swerdlow S (ed) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon, pp 88-107
4. Bennett JM, Catovsky D, Daniel MT et al (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189-199
5. Horny HP, Sotlar K, Valent P (2007) Diagnostic value of histology and immunohistochemistry in myelodysplastic syndromes. Leuk Res 31:1609-1616 doi: 10.1016/j.leukres.2007.05.010
6. Buesche G, Teoman H, Wilczak W et al (2008) Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes. Leukemia 22:313-322 doi: 10.1038/sj.leu.2405030
7. Schmitt-Graeff A, Mattern D, Köhler H, Hezel J, Lübbert M (2000) Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis. Pathologe 21:1-15 doi: 10.1007/s002920050001
8. Haase D, Germing U, Schanz J et al (2007) New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 110:4385-4395 doi: 10.1182/blood-2007-03-082404
9. Steidl C, Steffens R, Gassmann W et al (2005) Adequate cytogenetic examination in myelodysplastic syndromes: Analysis of 529 patients. Leuk Res 29:987 doi: 10.1016/j.leukres.2005.01.019
10. Haferlach T, Rieder H, Lillington DM et al (2007) Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes. Genes Chromosomes Cancer 46:494-499 doi: 10.1002/gcc.20433
11. List A, Kurtin S, Roe DJ et al (2005) Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352:549-557 doi: 10.1056/ NEJMoa041668
12. Giagounidis AA, Germing U, Strupp C et al (2005) Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup. Ann Hematol 84:569-571 doi: 10.1007/s00277-005-1054-0
13. Rüter B, Wijermans P, Claus R, Kunzmann R, Lübbert M (2007) Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7. Blood 110:1080-1082 doi: 10.1182/blood-2007-03-080630
14. Raj K, John A, Ho A et al (2007) CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia 21:1937-1944 doi: 10.1038/sj.leu.2404796
15. Knipp S, Hildebrand B, Kündgen A et al (2007) Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes. Cancer 110:345-352 doi: 10.1002/cncr.22779
16. Nolte F, Hofmann WK (2008) Myelodysplastic syndromes: Molecular pathogenesis and genomic changes. Ann Hematol 87:777-795 doi: 10.1007/ s00277-008-0502-z
17. Värkonyi J, Demeter J, Tordai A, Andrikovics H (2006) The significance of the hemochromatosis genetic variants in multiple myeloma in comparison to that of myelodysplastic syndrome. Ann Hematol 85:869-871 doi: 10.1007/s00277-006-0178-1
18. Loken MR, van de Loosdrecht A, Ogata K, Orfao A, Wells DA (2008) Flow cytometry in myelodysplastic syndromes: Report from a working conference. Leuk Res 32:5-17 doi: 10.1016/j.leukres.2007.04.020
19. Kern W, Haferlach C, Schnittger S, Haferlach T (2008) Dysplastic features detected by multiparameter flow cytometry in patients with MDS. Onkologie 31(S4):499
20. van de Loosdrecht AA, Westers TM, Westra AH et al (2008) Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood 111:1067-1077 doi: 10.1182/blood-2007-07-098764
21. Greenberg P, Cox C, LeBeau MM et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088
22. Germing U, Hildebrandt B, Pfeilstocker M et al (2005) Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia 19:2223-2231 doi: 10.1038/sj.leu.2403963
23. Malcovati L, Germing U, Kuendgen A et al (2007) Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25:3503-3510 doi: 10.1200/ JCO.2006.08.5696
24. Stauder R, Noesslinger T, Pfeilstöcker M et al (2008) Impact of age and comorbidity in myelodysplastic syndromes. J Natl Compr Canc Netw 6:927-934
25. Deschler B, Offermann B, Ihorst G et al (2008) Prospective multidimensional geriatric assessment in 210 patients >60 years with MDS/AML. Onkologie 31(S4):V495
26. Pelz D, Nachtkamp K, Kündgen A, Strupp C, Haas R, Germing U (2007) Influence of comorbidity factors on the prognosis of patients with myelodysplastic syndromes (MDS). Leuk Res 31(S1):15 doi: 10.1016/ S0145-2126(07)70053-X
27. Böhm A, Sperr WR, Leitner G et al (2008) Comorbidity predicts survival in myelodysplastic syndromes or secondary acute myeloid leukemia after allogeneic stem cell transplantation. Eur J Clin Invest 38:869-873
28. Platzbecker U, Bornhäuser M, Germing U et al (2008) Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biol Blood Marrow Transplant 14:1217-1225 doi: 10.1016/ j.bbmt.2008.08.006
29. Pitako JA, Haas PS, Van den Bosch J et al (2005) Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine. Ann Hematol 84(S13):25-31 doi: 10.1007/s00277-005-0007-y
30. Kantarjian H, Issa JP, Rosenfeld CS et al (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer 106:1794-1803 doi: 10.1002/cncr.21792
31. Silvermann LR, Demakos EP, Peterson BL et al (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B. J Clin Oncol 20:2429-2440 doi: 10.1200/JCO.2002.04.117
32. Park S, Grabar S, Kelaidi C et al (2008) Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: The GFM experience. Blood 111:574-582 doi: 10.1182/ blood-2007-06-096370
33. Stadler M, Germing U, Kliche KO et al (2004) A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 18:460-465 doi: 10.1038/ sj.leu.2403239
34. Nachtkamp K, Kündgen A, Strupp C, Gattermann N, Giagounidis A, Haas R, Germing U et al (2007) Influence of different treatment strategies on the prognosis of patients with MDS. Leuk Res 31(S1):14 doi: 10.1016/ S0145-2126(07)70052-8